Celadon Pharmaceuticals Regulatory News (CEL)

18 Jul 2008 07:00



CELSIS INTERNATIONAL PLC

("Celsis", "the Company" or "the Group")

Annual Information update

18 July 2008: Celsis International plc, the international life sciences products and laboratory services company, is pleased to provide an annual information update, in accordance with the requirements of the Prospectus Rule 5.2. This update refers to information that has been published or made available by the Company to the public over the twelve months preceding this announcement.  To avoid a statement of unnecessary length information is referred to in this update rather than included in full.

In accordance with Rule 5.2.7 of the Prospectus Rules, the information referred to in this update was up to date at the time the information was published but some information may now be out of date.  This annual information update does not constitute an offer of securities addressed to any person and should not be relied on by any person.

1. Announcements made via the Regulatory News Service ("RNS"), a Regulatory Information Service ("RIS"). 

Copies of all announcements can be obtained from the Regulatory News Service of the London Stock Exchange.

2. Documents filed at Companies House

The documents listed below were filed with the Registrar of Companies in England and Wales on or around the dates indicated.  Copies of these documents can be obtained from Companies House.

3. Documents sent to Shareholders

The documents listed below have been despatched by the Company to holders of its securities on or around the following dates.

4. Documents submitted to the UK Listing Authority

Copies of the following documents have been submitted to the UK Listing Authority for inspection at their Document Viewing Facility on or around the following dates and can be obtained from the Company Secretary, Celsis International plc, 1010 Cambourne Business Park, Cambourne, Cambridge, CB23 6DP.

Notes to editors

Celsis International plc

Celsis International plc is a leading international provider of innovative life science products and laboratory services to the pharmaceutical and consumer products industries. Each Celsis division has the capacity to deliver substantial time and cost savings to its customers, in addition to ensuring product quality and safety for consumers. Celsis' extensive client base includes many of the world's leading pharmaceutical and consumer products companies. The Company is listed on the London Stock Exchange (CEL.L).

Celsis Rapid Detection division utilises proprietary enzyme technology to develop and supply diagnostic testing instruments and consumables for the rapid detection of microbial contamination in pharmaceutical and consumer products. These rapid testing systems provide significant economic value by reducing the time it takes to test and release raw materials, in process and finished goods to market. 

Celsis Analytical Services division provides cost effective outsourced laboratory testing services to pharmaceutical companies. Its comprehensive service offerings include a full spectrum of laboratory services from drug development and discovery to analytical chemistry and biological sciences to stability storage and testing. 

Celsis In Vitro Technologies (Celsis IVT) employs proprietary expertise in hepatocyte (liver cell) technology to supply in vitro testing products to the pharmaceutical industry. Celsis IVT's consumable testing products screen drug compounds for liver toxicity early in the drug discovery process, thereby reducing the time and cost of further development or trial on those compounds which will not be properly metabolised by the human liver. 

Further information can be found on its website at www.celsis.com.